DRDO released a brief guideline on Twitter regarding the usage of the 2-DG drug in COVID patients.
The new drug by DRDO is the current sensation in COVID-19 treatment. On Tuesday, the DRDO on Twitter issued “Directions for use of 2-DG in COVID-19 patients as per DCGI approval” This "Made-in-India" drug 2-Deoxy-D-Glucose was developed by DRDO.
‘2-DG must be prescribed to patients who developed moderate to severe forms of SARS-CoV-2 infections and caution must be exercised while using it on people with comorbidities.’
Previously, the first batch of this drug was released on 17 May by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan. Key takeaways from the guidelines
• The drug 2-DG must only be prescribed to COVID patients who have been hospitalized by moderate to severe forms of the infection.
• The drug should be prescribed as early as possible to COVID patients who have developed moderate to severe forms of the infection for a maximum duration of up to 10 days.
• Use of 2-DG in COVID patients with uncontrolled diabetes, severe hepatic and renal impairment, severe cardiac problem, and acute respiratory distress syndrome must be exercised with caution.
Advertisement
• Dr. Reddy's Laboratories is the point of contact for the medicine supply to hospitals, in case of requests from patients or their attendants.
Advertisement
Source-Medindia